Your browser doesn't support javascript.
loading
Mesenchymal stem cells: A living carrier for active tumor-targeted delivery.
Zhang, Tianyuan; Lin, Ruyi; Wu, Honghui; Jiang, Xinchi; Gao, Jianqing.
Afiliación
  • Zhang T; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China.
  • Lin R; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Wu H; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Jiang X; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China.
  • Gao J; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China; Cancer Center, Zhejiang Unive
Adv Drug Deliv Rev ; 185: 114300, 2022 06.
Article en En | MEDLINE | ID: mdl-35447165

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Países Bajos